Get the Stockscreener App
0.7598
5.35%
0.0421
Pds Biotechnology Corporation stock is traded at $0.7598, with a volume of 1.09M.
It is up +5.35% in the last 24 hours and down -19.14% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$0.7177
Open:
$0.8
24h Volume:
1.09M
Relative Volume:
1.50
Market Cap:
$37.09M
Revenue:
-
Net Income/Loss:
$-40.56M
P/E Ratio:
-0.6494
EPS:
-1.17
Net Cash Flow:
$-35.28M
1W Performance:
+1.41%
1M Performance:
-19.14%
6M Performance:
-46.38%
1Y Performance:
-64.83%
1-Day Range:
$0.7201
$0.8082
1-Week Range:
$0.703
$0.815
52-Week Range:
$0.703
$2.46
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
0.7573 | 39.27M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.80 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.22 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
466.12 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.58 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.71 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
PDS Biotech secures FDA meeting to discuss accelerated approval pathway By Investing.com - Investing.com Nigeria
PDS Biotech secures FDA meeting to discuss accelerated approval pathway - Investing.com
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration ('FDA”) - The Manila Times
PDS Biotech (Nasdaq: PDSB) Plans FDA Talk on PFS Endpoint in VERSATILE-003 Trial - Stock Titan
How supply chain issues affect PDS Biotechnology Corporation stockGlobal Markets & Stock Timing and Entry Methods - Newser
Energy Moves: How interest rate cuts could boost PDS Biotechnology Corporation stock2025 Volatility Report & Capital Efficiency Focused Ideas - moha.gov.vn
Adversity is less terrifying than hope: PDS Biotechnology Corporation (PDSB) - Setenews
B. Riley Cuts PDS Biotechnology (NASDAQ:PDSB) Price Target to $3.00 - Defense World
History Review: How interest rate cuts could boost PDS Biotechnology Corporation stockPortfolio Growth Summary & Precise Buy Zone Tips - BỘ NỘI VỤ
PDS Biotechnology price target lowered to $3 from $5 at B. Riley - Yahoo Finance
B. Riley Securities Maintains PDS Biotechnology (PDSB) Buy Recommendation - Nasdaq
B. Riley Adjusts Price Target on PDS Biotechnology to $3 From $5, Maintains Buy Rating - MarketScreener
Can PDS Biotechnology Corporation stock reach $100 price targetMarket Performance Report & Growth Focused Investment Plans - newser.com
PDS Biotechnology Shares Face Market Pressure Despite Clinical Promise - Ad-hoc-news.de
What dividend safety score for PDS Biotechnology Corporation stock2025 Market Overview & Real-Time Volume Analysis Alerts - newser.com
Why PDS Biotechnology Corporation stock is recommended by analysts2025 Top Decliners & Growth Focused Stock Reports - newser.com
Earnings visualization tools for PDS Biotechnology CorporationOil Prices & Verified Technical Signals - newser.com
PDS Biotechnology Corporation’s volatility index tracking explainedInflation Watch & Breakout Confirmation Alerts - newser.com
Advanced analytics toolkit walkthrough for PDS Biotechnology CorporationCPI Data & Daily Oversold Bounce Ideas - newser.com
Is PDS Biotechnology Corporation stock a good choice for value investorsInflation Watch & Safe Entry Point Identification - newser.com
It makes sense and dollars to buy PDS Biotechnology Corporation (PDSB) stock - Setenews
Is PDS Biotechnology Corporation stock entering bullish territoryJuly 2025 Highlights & Consistent Growth Equity Picks - newser.com
PDS Biotechnology Corp (EU6.DU) stock price, news, quote and history - Yahoo Finance Singapore
Tools to assess PDS Biotechnology Corporation’s risk profilePortfolio Performance Report & Consistent Return Investment Signals - newser.com
Multi factor analysis applied to PDS Biotechnology CorporationWeekly Volume Report & Weekly Chart Analysis and Guides - newser.com
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2025 Earnings Call Transcript - Insider Monkey
Will PDS Biotechnology Corporation stock go up soonWeekly Investment Recap & AI Based Buy and Sell Signals - newser.com
Will PDS Biotechnology Corporation stock reach all time highs in 2025Earnings Growth Summary & Long-Term Safe Return Strategies - newser.com
PDS Biotechnology: Q3 Earnings Snapshot - New Haven Register
PDS Biotechnology Trims Losses And Aims For Accelerated Drug Approval - Finimize
PDS Biotechnology: Promising Trial Results and Financial Update - TipRanks
Earnings call transcript: PDS Biotech beats EPS expectations in Q3 2025 - Investing.com UK
HC Wainwright & Co. Maintains PDS Biotechnology (PDSB) Buy Recommendation - Nasdaq
PDS Biotechnology Corp (PDSB) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Q3 2025 Earnings Report - MarketBeat
Earnings call transcript: PDS Biotech beats EPS expectations in Q3 2025 By Investing.com - Investing.com South Africa
PDS Biotechnology Corporation (PDSB) Q3 FY2025 earnings call transcript - Yahoo Finance
PDS biotechnology Q3 net loss narrows on lower operating expenses - MarketScreener
PDS Biotechnology Corporation Completes VERSATILE-002 Phase 2 Trial, Pursues Expedited Approval for HPV16-Positive Head and Neck Cancer Treatment - Quiver Quantitative
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update - The Manila Times
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[8-K] PDS Biotechnology Corp Reports Material Event | PDSB SEC FilingForm 8-K - Stock Titan
PDS Biotech (Nasdaq: PDSB) to seek accelerated approval in VERSATILE-003 on 6.3-month PFS - Stock Titan
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pds Biotechnology Corporation Stock (PDSB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Glover Stephen C. | Director |
Feb 28 '25 |
Buy |
1.66 |
15,061 |
25,001 |
78,851 |
0.73%
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):